Clinical trials · Pittsburgh, PA
Hepatocellular Carcinoma clinical trials in Pittsburgh
We’re tracking 15 recruiting hepatocellular carcinoma studies with a site in or near Pittsburgh — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Pittsburgh
- NCT07223424RecruitingPhase 2
Patient preference study: shot vs infusion for immunotherapy
This study compares two ways to take immunotherapy drugs (nivolumab or pembrolizumab): as a shot under the skin (subcutaneous) versus an infusion into a vein (intravenous). It looks at which method patients prefer and is for people with certain advanced cancers where these drugs are already approved.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06427941RecruitingPhase 1
Study of BGB-B2033 drug for advanced solid tumors
This trial tests a new drug, BGB-B2033, alone or with other treatments, for people with advanced liver, stomach, lung, or germ cell cancers that have not responded to standard therapy. The goal is to see if the drug is safe and works against these tumors.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05733598RecruitingPhase 2
RP2 plus standard treatment for advanced liver or bile cancers
This Phase 2 trial studies whether RP2, added to standard second-line treatment, can improve outcomes for people with advanced liver cancer or bile duct/gallbladder cancer. It may help by training the immune system to better attack the cancer after the cancer has already grown despite prior treatment.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06698250RecruitingPhase 2
Study of triple therapy for untreated liver cancer
This study tests a combination of three drugs (zanzalintinib, durvalumab, and tremelimumab) for people with liver cancer that cannot be removed by surgery and who have not received prior systemic treatment. The goal is to see if this combination can shrink or slow the growth of the cancer.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT03539822RecruitingPhase 1/Phase 2
Cabozantinib and immunotherapy for advanced stomach or bowel cancers
This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04114136RecruitingPhase 2
Study tests pembrolizumab or nivolumab plus a diabetes-like drug
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06600321RecruitingPhase 1
Study of ALN-BCAT for liver cancer
This trial tests a new drug called ALN-BCAT for people with advanced liver cancer (hepatocellular carcinoma) that has a specific genetic change. If you have already tried at least one treatment, this study may be an option for you.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06811116RecruitingPhase 1/Phase 2
Sapanisertib plus cabozantinib for advanced liver cancer
This trial studies a combination of two drugs for advanced liver cancer with a specific gene change. The goal is to see if adding sapanisertib to the usual cabozantinib treatment helps people live longer without their cancer growing.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Pittsburgh, PennsylvaniaAges 1–30 - NCT07419841RecruitingPhase 1
A study of CTX-10726 for certain advanced cancers
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06921785RecruitingPhase 3
Combination therapy for first-line liver cancer treatment
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT03959800Recruiting
Study of the causes of childhood liver tumors
This study looks at why childhood liver tumors happen by using samples and information from children who have had a liver tumor and from their close family members. It may help researchers understand the biology of these tumors and guide better treatments in the future.
Pittsburgh, PennsylvaniaAges birth–99 years - NCT05168163RecruitingPhase 2
Atezolizumab plus targeted drug for advanced liver cancer
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06061328Enrolling by invitation
Project OASIS: Finding better ways to improve care for cirrhosis
This trial tests different approaches to help doctors and hospitals improve care for veterans with cirrhosis. If you have cirrhosis and are not post-transplant or currently being treated for liver cancer, you might be able to join and help find the best strategies.
Pittsburgh, PennsylvaniaAges 18 years+
Hear when a new Hepatocellular Carcinoma trial opens near Pittsburgh, PA
We’ll email you when one opens near Pittsburgh, PA — at most once a week, no account needed, unsubscribe anytime.
Hepatocellular Carcinoma trials in other cities
Where these studies are running near Pittsburgh
Institutions with a site for the recruiting hepatocellular carcinoma studies listed above.
- UPMC Hillman Cancer Center · 8 studies
- UPMC Children's Hospital of Pittsburgh · 2 studies
- Allegheny General Hospital
- Clinical Trial Site
- Exelixis Clinical Site
- Research Site
- VA Pittsburgh Healthcare System
What taking part in a hepatocellular carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting hepatocellular carcinoma studies in Pennsylvania.
Common questions
- Are there hepatocellular carcinoma clinical trials near Pittsburgh?
- Yes. We're currently tracking 15 recruiting hepatocellular carcinoma studies with a site near Pittsburgh, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hepatocellular carcinoma study near Pittsburgh?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pittsburgh to take part?
- Not necessarily. These studies have a site near Pittsburgh, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hepatocellular carcinoma studies open near Pittsburgh regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.